M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.
26 Oct, 2022 | 14:32h | UTCCommentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News